Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Loose, L. D.
Right arrow Articles by Ting, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Loose, L. D.
Right arrow Articles by Ting, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 British Society for Rheumatology

Reduction of Acute-Phase Proteins with Tenidap Sodium, a Cytokine-Modulating Anti-Rheumatic Drug

L. D. Loose*, J. D. Sipe{dagger}, D. S. Kirby*, A. R. Kraska*, E. S. Weiner*, W. R. Shanahan*, M. R. G. Leeming{ddagger}, P. Farrow{ddagger}, C. B. Stack* and N. Ting*

* Central Research Division, Pfizer Inc., Groton, CT06340
{dagger} Boston University School of Medicine Boston, MA 02118, USA
{ddagger} Central Research Division, Pfizer Inc., Sandwich, Kent

Correspondence to: Correspondence to L. D. Loose, Central Research Division, Pfizer Inc, Eastern Point Road, Groton, CT 06340, USA.


  Abstract

Four independent studies have investigated and compared the effects of tenidap sodium, naproxen and placebo on CRP in patients with active RA. One of these studies also investigated the effects of tenidap and naproxen on serum amyloid A (SAA) concentrations and ESR. The duration of the four studies ranged between 2 weeks and 24 weeks, and depending on the study, tenidap sodium was administered orally in doses of 40-120 mg/day and naproxen in doses of 1000 mg/day. In all four studies serum CRP concentrations in tenidap-treated patients had decreased significantly from baseline at the time of final assessment. The decrease in CRP concentration in tenidap-treated patients was observed as early as 1 week after initiation of therapy and was sustained for up to 6 months, the last assessment timepoint. CRP concentrations in naproxen-treated and placebo patients were essentially unchanged. The decreases from baseline observed in tenidap-treated patients were significantly greater than the changes observed in naproxen-treated or placebo patients. After 24 weeks of tenidap treatment the decrease in CRP was paralleled by significant decreases in SAA concentration and ESR. The finding that tenidap sodium rapidly, consistently and significantly lowered CRP serum concentrations differentiates tenidap sodium from the NSAID, naproxen. This could possibly have important therapeutic implications given that other long-term investigations have shown that reducing serum CRP and SAA concentrations correlates with a reduction in radio-graphically-assessed disease progression.

KEY WORDS: Rheumatoid arthritis, Tenidap, C-reactive protein, Serum amyloid A, Naproxen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.